Patients (or carers) must be provided with the MCP Consent Form to read and provide written consent. Patient must be made aware that the information provided will be used by PharmaPrograms to facilitate the program and support the patient’s treatment. Because third parties are involved in this process, informed consent must be gained from the patient. The patient must be aware that their prescribing doctor of the medicinal cannabis, can request from MCP information on when the medication has been dispensed. This is to ensure the patient’s health professionals are working together to ensure maximum benefits from the medication are achieved.
Patients should be supplied with a copy of the QUM information leaflet to ensure appropriate use of medications information has been provided to the patient. Traditional sources of prescription medicines information, such as a Consumer Medicine Information (CMI) leaflet, are not supplied for all medicinal cannabis medicines. Each sponsor manufacturer of Medicinal Cannabis may have information that is suitable for the public. If it is available to Australian patients, it will be contained in the MCP.
As part of the terms and conditions of the program, pharmacies have agreed to charge the patient a price no more than the listed Maximum Price to Patient.